- Author:
Hye-Ran MOON
1
;
Seon Ju MUN
;
Tae Hun KIM
;
Hyemin KIM
;
Dukjin KANG
;
Suran KIM
;
Ji Hyun SHIN
;
Dongho CHOI
;
Sun-Ju AHN
;
Myung Jin SON
Author Information
- Publication Type:SPECIAL REPORT
- From:International Journal of Stem Cells 2024;17(2):120-129
- CountryRepublic of Korea
- Language:EN
- Abstract: Recent amendments to regulatory frameworks have placed a greater emphasis on the utilization of in vitro testing platforms for preclinical drug evaluations and toxicity assessments. This requires advanced tissue models capable of accurately replicating liver functions for drug efficacy and toxicity predictions. Liver organoids, derived from human cell sources, offer promise as a reliable platform for drug evaluation. However, there is a lack of standardized quality evaluation methods, which hinders their regulatory acceptance. This paper proposes comprehensive quality standards tailored for liver organoids, addressing cell source validation, organoid generation, and functional assessment. These guidelines aim to enhance reproducibility and accuracy in toxicity testing, thereby accelerating the adoption of organoids as a reliable alternative or complementary tool to animal testing in drug development. The quality standards include criteria for size, cellular composition, gene expression, and functional assays, thus ensuring a robust hepatotoxicity testing platform.